Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2024-04, Vol.20 (4), p.33, Article 33 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 33 |
| container_title | Molecular and clinical oncology |
| container_volume | 20 |
| creator | Natori, Daisuke Ozasa, Hiroaki Shima, Yusuke Mizumoto, Chisaki Suminaga, Keiichiro Nomizo, Takashi Ajimizu, Hitomi Yoshida, Hironori Hirai, Toyohiro |
| description | The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma. |
| doi_str_mv | 10.3892/mco.2024.2731 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10928651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A790391263</galeid><sourcerecordid>A790391263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-564b64926c0f9bace95ee938f6c7f93d7f8e2be84f1c24b85461615a40783eb33</originalsourceid><addsrcrecordid>eNptUkGP1SAYbIzG3ax79GpIPPdJgdLixTw3rpps4kE9E0o_XjG0VKDuPk_-hY3_0F8izVufbmI4QIaZYb4wRfG0whvaCvJi1H5DMGEb0tDqQXFKMBOlYFw8PJ5rfFKcx2g7XFMqKBPt4-KEtqzhlDanxc-Pi9YQo1kcSgFUGmFKyBvklmmHtJo0BKQ93NiYbEaubRrQ618_bjU4h9x-nAc_qgM8w9gF7-z3ZVQdMt45f71qgk3Ljc1YltlJu6WHHukBRp8GCGrev0Tb_FQEFGD2IT0pHhnlIpzf7WfF58s3ny7elVcf3r6_2F6VmmGeypqzjjNBuMZGdEqDqAEEbQ3XjRG0b0wLpIOWmUoT1rU14xWvasVw01LoKD0rXh1856Ubodd58qCcnEPOGvbSKyvv30x2kDv_TVZYkJbXVXZ4fucQ_NcFYpJf_BKmHFoSUfP8A6Jt_rJ2yoG0k_HZTY82arltBKaiInxNs_kPK68eRqv9BMZm_J6gPAh08DEGMMfkFZZrPWSuh1zrIdd6ZP6zf8c9sv-Ugf4GmK-7LQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956049987</pqid></control><display><type>article</type><title>Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Natori, Daisuke ; Ozasa, Hiroaki ; Shima, Yusuke ; Mizumoto, Chisaki ; Suminaga, Keiichiro ; Nomizo, Takashi ; Ajimizu, Hitomi ; Yoshida, Hironori ; Hirai, Toyohiro</creator><creatorcontrib>Natori, Daisuke ; Ozasa, Hiroaki ; Shima, Yusuke ; Mizumoto, Chisaki ; Suminaga, Keiichiro ; Nomizo, Takashi ; Ajimizu, Hitomi ; Yoshida, Hironori ; Hirai, Toyohiro</creatorcontrib><description>The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2024.2731</identifier><identifier>PMID: 38476337</identifier><language>eng</language><publisher>England: Spandidos Publications</publisher><subject>Adrenal glands ; Bendamustine ; Biopsy ; Cancer ; Cancer therapies ; Case Report ; Case reports ; Chemotherapy ; Clinical trials ; Development and progression ; Drug therapy ; Endoscopy ; Health aspects ; Lung cancer ; Lymphatic system ; Lymphoma ; Medical colleges ; Metastasis ; Non-Hodgkin's lymphomas ; Oncology, Experimental ; Patients ; Remission (Medicine) ; Respiratory agents ; Stomach ; Tomography ; Tumors ; Vincristine</subject><ispartof>Molecular and clinical oncology, 2024-04, Vol.20 (4), p.33, Article 33</ispartof><rights>Copyright: © 2024 Natori et al.</rights><rights>COPYRIGHT 2024 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2024</rights><rights>Copyright: © 2024 Natori et al. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c406t-564b64926c0f9bace95ee938f6c7f93d7f8e2be84f1c24b85461615a40783eb33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928651/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928651/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38476337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Natori, Daisuke</creatorcontrib><creatorcontrib>Ozasa, Hiroaki</creatorcontrib><creatorcontrib>Shima, Yusuke</creatorcontrib><creatorcontrib>Mizumoto, Chisaki</creatorcontrib><creatorcontrib>Suminaga, Keiichiro</creatorcontrib><creatorcontrib>Nomizo, Takashi</creatorcontrib><creatorcontrib>Ajimizu, Hitomi</creatorcontrib><creatorcontrib>Yoshida, Hironori</creatorcontrib><creatorcontrib>Hirai, Toyohiro</creatorcontrib><title>Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.</description><subject>Adrenal glands</subject><subject>Bendamustine</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Endoscopy</subject><subject>Health aspects</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Lymphoma</subject><subject>Medical colleges</subject><subject>Metastasis</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Respiratory agents</subject><subject>Stomach</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Vincristine</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptUkGP1SAYbIzG3ax79GpIPPdJgdLixTw3rpps4kE9E0o_XjG0VKDuPk_-hY3_0F8izVufbmI4QIaZYb4wRfG0whvaCvJi1H5DMGEb0tDqQXFKMBOlYFw8PJ5rfFKcx2g7XFMqKBPt4-KEtqzhlDanxc-Pi9YQo1kcSgFUGmFKyBvklmmHtJo0BKQ93NiYbEaubRrQ618_bjU4h9x-nAc_qgM8w9gF7-z3ZVQdMt45f71qgk3Ljc1YltlJu6WHHukBRp8GCGrev0Tb_FQEFGD2IT0pHhnlIpzf7WfF58s3ny7elVcf3r6_2F6VmmGeypqzjjNBuMZGdEqDqAEEbQ3XjRG0b0wLpIOWmUoT1rU14xWvasVw01LoKD0rXh1856Ubodd58qCcnEPOGvbSKyvv30x2kDv_TVZYkJbXVXZ4fucQ_NcFYpJf_BKmHFoSUfP8A6Jt_rJ2yoG0k_HZTY82arltBKaiInxNs_kPK68eRqv9BMZm_J6gPAh08DEGMMfkFZZrPWSuh1zrIdd6ZP6zf8c9sv-Ugf4GmK-7LQ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Natori, Daisuke</creator><creator>Ozasa, Hiroaki</creator><creator>Shima, Yusuke</creator><creator>Mizumoto, Chisaki</creator><creator>Suminaga, Keiichiro</creator><creator>Nomizo, Takashi</creator><creator>Ajimizu, Hitomi</creator><creator>Yoshida, Hironori</creator><creator>Hirai, Toyohiro</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20240401</creationdate><title>Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report</title><author>Natori, Daisuke ; Ozasa, Hiroaki ; Shima, Yusuke ; Mizumoto, Chisaki ; Suminaga, Keiichiro ; Nomizo, Takashi ; Ajimizu, Hitomi ; Yoshida, Hironori ; Hirai, Toyohiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-564b64926c0f9bace95ee938f6c7f93d7f8e2be84f1c24b85461615a40783eb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adrenal glands</topic><topic>Bendamustine</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Endoscopy</topic><topic>Health aspects</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Lymphoma</topic><topic>Medical colleges</topic><topic>Metastasis</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Respiratory agents</topic><topic>Stomach</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Vincristine</topic><toplevel>online_resources</toplevel><creatorcontrib>Natori, Daisuke</creatorcontrib><creatorcontrib>Ozasa, Hiroaki</creatorcontrib><creatorcontrib>Shima, Yusuke</creatorcontrib><creatorcontrib>Mizumoto, Chisaki</creatorcontrib><creatorcontrib>Suminaga, Keiichiro</creatorcontrib><creatorcontrib>Nomizo, Takashi</creatorcontrib><creatorcontrib>Ajimizu, Hitomi</creatorcontrib><creatorcontrib>Yoshida, Hironori</creatorcontrib><creatorcontrib>Hirai, Toyohiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Natori, Daisuke</au><au>Ozasa, Hiroaki</au><au>Shima, Yusuke</au><au>Mizumoto, Chisaki</au><au>Suminaga, Keiichiro</au><au>Nomizo, Takashi</au><au>Ajimizu, Hitomi</au><au>Yoshida, Hironori</au><au>Hirai, Toyohiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>20</volume><issue>4</issue><spage>33</spage><pages>33-</pages><artnum>33</artnum><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.</abstract><cop>England</cop><pub>Spandidos Publications</pub><pmid>38476337</pmid><doi>10.3892/mco.2024.2731</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2024-04, Vol.20 (4), p.33, Article 33 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10928651 |
| source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adrenal glands Bendamustine Biopsy Cancer Cancer therapies Case Report Case reports Chemotherapy Clinical trials Development and progression Drug therapy Endoscopy Health aspects Lung cancer Lymphatic system Lymphoma Medical colleges Metastasis Non-Hodgkin's lymphomas Oncology, Experimental Patients Remission (Medicine) Respiratory agents Stomach Tomography Tumors Vincristine |
| title | Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A42%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20treatment%20of%20lung%20cancer%20coexisting%20with%20B%E2%80%91cell%20lymphoma%20with%20pembrolizumab%20following%20rituximab%E2%80%91included%20chemotherapy:%20A%20case%20report&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=Natori,%20Daisuke&rft.date=2024-04-01&rft.volume=20&rft.issue=4&rft.spage=33&rft.pages=33-&rft.artnum=33&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2024.2731&rft_dat=%3Cgale_pubme%3EA790391263%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2956049987&rft_id=info:pmid/38476337&rft_galeid=A790391263&rfr_iscdi=true |